What is Rapport Therapeutics, Inc.'s D&A?

Rapport Therapeutics, Inc. (RAPP) reported D&A of $227K in Q1 2026.

How has Rapport Therapeutics, Inc.'s D&A changed year-over-year?

Rapport Therapeutics, Inc.'s D&A decreased by 7.0% year-over-year, from $244K to $227K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Rapport Therapeutics, Inc. RAPP D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

Supernus PharmaceuticalsSUPN

$26.13M+28.2%

Xenon PharmaceuticalsXENE

$587K-10.9%

Praxis Precision Medicines, Inc.PRAX

$39K-17.0%

BiohavenBHVN

$2.37M+5.3%

Septerna, Inc.SEPN

$421K+6.0%

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.86B+309%

Enterprise value$1.79B+352%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s D&A?: Rapport Therapeutics, Inc. (RAPP) reported D&A of $227K in Q1 2026.
How has Rapport Therapeutics, Inc.'s D&A changed year-over-year?: Rapport Therapeutics, Inc.'s D&A decreased by 7.0% year-over-year, from $244K to $227K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.